Clinical Trials Logo

Aplastic Anemia clinical trials

View clinical trials related to Aplastic Anemia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04439006 Completed - Clinical trials for Myelodysplastic Syndrome

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Start date: October 23, 2020
Phase: Phase 1
Study type: Interventional

This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing.

NCT ID: NCT04403321 Completed - Aplastic Anemia Clinical Trials

Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients

Start date: July 1, 2020
Phase: Phase 2
Study type: Interventional

This is a randomized, open-label, phase II study to compare the efficacy of eltrombopag combined with tacrolimus to eltrombopag alone in Chinese subjects with refractory or relapsed aplastic anemia. The safety would also be evaluated. Patients would be randomized to receive eltrombopag alone or eltrombopag combined with tacrolimus. Treatment with eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day, or the best response was achieved. Tacrolimus will be given at 1mg bid with the target trough concentration of 4-10 ng/mL throughout the study. The hematological response rate and safety will be recorded and compared at 3, 6 months and 1 year after starting the study treatment (Week 13, 26 and 52).

NCT ID: NCT04350606 Completed - Aplastic Anemia Clinical Trials

A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia

Start date: July 25, 2020
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy and safety of PF-06462700 administered intravenously at 40 mg/kg/day for 4 days in Japanese participants with moderate and above aplastic anemia for making an approval application in Japan.

NCT ID: NCT04128943 Completed - Aplastic Anemia Clinical Trials

Electronic Patient-reported Outcome Monitoring in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

ePRO-AA-PNH
Start date: November 1, 2019
Phase:
Study type: Observational

Aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are interrelated and very rare diseases. Therefore, little data about clinical characteristics, especially the variety of symptoms in the course of the respective disease are available. As a consequence, patients may be left on their own between infrequent follow-ups at a specialist center. A web-based symptom-monitoring application can support selfmanagement and patient empowerment and promotes a patient- centered interdisciplinary team approach in the context of a "disease management program". This pilot study is to investigate usability and feasibility of the electronic Patient-Reported Outcome (ePRO) application in AA/PNH by assessing recruitment, app utilization, data collection, functionality, acceptability after using and working with the ePRO application.

NCT ID: NCT04095936 Completed - Aplastic Anemia Clinical Trials

Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia

Start date: December 3, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the hematological responses based on the response assessment criteria defined in this study (the 531-004 response assessment criteria) when AMG531 is subcutaneously (SC)-administered with ciclosporin A (CsA) therapy for 6 months in patients with aplastic anemia (AA) who were previously untreated with immunosuppressive therapy.

NCT ID: NCT03988608 Completed - Aplastic Anemia Clinical Trials

Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.

Start date: December 9, 2019
Phase: Phase 2
Study type: Interventional

This is a non-randomized, open-label, phase II study to assess the efficacy and safety of eltrombopag in Chinese subjects with refractory or relapsed severe aplastic anemia (SAA). Treatment with eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day. The hematological response rate will be assessed at 3, 6 months and 1 year after starting the study treatment (Week 13, 26 and 52).

NCT ID: NCT03957694 Completed - Aplastic Anemia Clinical Trials

Study of AMG531(Romiplostim) in Patients With Aplastic Anemia

Start date: April 25, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the hematological responses based on the response assessment criteria when AMG531 is subcutaneous (SC)-administered with anti-human thymocyte immunoglobulin (ATG) + ciclosporin A (CsA) therapy for 6 months in patients with aplastic anemia (AA) who were previously untreated with immunosuppressive therapy.

NCT ID: NCT03896971 Completed - Aplastic Anemia Clinical Trials

Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia

Start date: November 15, 2019
Phase: Phase 4
Study type: Interventional

To the investigator's Knowledge this is the first study that will assess Treatment with thrombopoietin Mimetic plus immunosuppressiveTherapy in Egyptian Patients with Aplastic Anaemia. Aim of the work : 1. To evaluate the efficacy, tolerability and toxicity of the combination of thrombopoietin mimetic and immunosuppressive therapy in Egyptian patients with AA. 2. To study the influence of this combination on patients' quality of life. 3. To access evolution to paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome , acute leukemia or development of fibrosis

NCT ID: NCT03318159 Completed - Clinical trials for Myelodysplastic Syndromes

Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients

Start date: April 20, 2018
Phase: Phase 2
Study type: Interventional

To investigate the efficacy of posaconazole as prophylaxis antifungal agent in aplastic anemia / hypoplastic myelodysplastic syndrome (AA/hMDS) patients undergoing antithymocyte globulin (ATG) treatment

NCT ID: NCT03208647 Completed - Aplastic Anemia Clinical Trials

Multi Center Case Control Study on Multiple Risk Factors of Aplastic Anemia

MCSAA
Start date: January 1, 2003
Phase: N/A
Study type: Observational

To ascertain the risk factors of AA in ZheJiang Province of China at the moment, especially the comprehensive multiple factors risks. The author conducted a case-control research included 338 AA cases and 1464 controls. Subjects were surveyed using same standard questionnaire including personal data, past histories of diseases, family history and histories of occupational and daily exposure to harmful substances. Single and multiple Logistic regression analyses were made using SPSS17.0 on the dates to study potential factors in the development of AA.